Peptide Database

AOD9604 (Advanced Obesity Drug 9604) is a modified fragment of human growth hormone (hGH fragment 176-191). It was developed at Monash University in Australia specifically to isolate the fat-reducing effects of GH without its growth-promoting or diabetogenic properties. It received GRAS (Generally Recognized as Safe) status from the FDA as a food ingredient.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a mitochondrial-derived peptide consisting of 16 amino acids. It was discovered in 2015 and has been described as an exercise mimetic due to its effects on metabolic regulation, insulin sensitivity, and physical performance.

Retatrutide (LY3437943) is a triple agonist peptide targeting GIP, GLP-1, and glucagon receptors. Developed by Eli Lilly, it represents the next generation of incretin-based therapies. Phase 2 clinical trials have shown unprecedented weight loss results, and Phase 3 trials are ongoing.

Semaglutide is a GLP-1 receptor agonist FDA-approved under brand names Ozempic® (T2D), Wegovy® (weight management), and Rybelsus® (oral T2D). It represents a major advance in metabolic medicine with demonstrated efficacy for glycemic control, weight management, and cardiovascular risk reduction.

Tesamorelin (brand name Egrifta®) is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It stimulates the pituitary gland to produce growth hormone.

Tirzepatide (brand names Mounjaro® for T2D, Zepbound® for weight management) is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly. It is FDA-approved for type 2 diabetes management and chronic weight management in adults with obesity or overweight with at least one weight-related condition.